RANI THERAPEUTICS HLD. news, videos and press releases
For more news please use our advanced search feature.
RANI THERAPEUTICS HLD. - More news...
RANI THERAPEUTICS HLD. - More news...
- Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
- Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
- Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
- Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
- Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
- Rani Therapeutics to Participate in Upcoming Investor Conferences
- Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist
- Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants
- Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit
- Rani Therapeutics to Participate in September Investor Conferences
- Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update
- Rani Therapeutics to Participate in August Investor Conferences
- Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
- Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
- Rani Therapeutics to Participate in May Investor Conferences
- Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
- Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
- Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
- Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
- Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)
- Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
- Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
- Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results
- The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study
- Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
- Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
- Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
- Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
- Rani Therapeutics to Participate in September Investor Conferences
- Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
